An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

Trial Profile

An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Miltefosine (Primary) ; Paromomycin (Primary) ; Sodium stibogluconate; Sodium stibogluconate
  • Indications Visceral leishmaniasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Apr 2018 According to a Drugs for Neglected Disease initiative (DNDi) media release, this clinical trial will be conducted under the umbrella of the new Afri-KA-DIA Consortium composed of ten academic and research partners who have conducted innovative VL clinical trials in eastern Africa over the past 12 years.
    • 13 Apr 2018 According to a Drugs for Neglected Disease initiative (DNDi) media release, till date 20 patients has been enrolled in this study trial sites in Ethiopia, Kenya, and Sudan.
    • 05 Mar 2018 Planned End Date changed from 31 Aug 2019 to 30 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top